Pheon Therapeutics Expands Board with Appointment of Dr. Enoch Kariuki
- Dr. Kariuki brings a wealth of experience in ADCs, across corporate strategy, finance and operations
- Advancement of Pheon’s differentiated ADC pipeline, accelerating first program, PHN-010, into clinical development this year
London UK, 10 September 2024 – Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, today announces the appointment of accomplished biotech executive, Enoch Kariuki, Pharm.D., to its Board of Directors as an independent, non-executive director.
